Research & Markets: Zanidip (Lercanidipine), an In-house Developed ...
This pharmaceutical company intelligence report provides a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
Recordati was established in 1926 in Milan, Italy and is now listed on the Italian Stock Exchange
Italian Stock Exchange (ISE)
The Milan-based stock exchange, which came into effect after the unification of Italy's ten national exchanges in 1991. All listed securities are traded electronically. The main indexes are the MIB and the MIBTEL, based on the prices of all listed shares, and the MIB 30, based on a sample of the 30 most liquid and highly capitalized shares.. The company employs more than 1,900 people and its products are sold in about 100 countries. Recordati markets products in the following fields: Cardiovascular, Central Nervous System, Gastroenterology gas
tro·enter·o·log
ic (-
-l/Urology; Respiratory and Anti-infectives. The company is active in the following areas of research: Cardiovascular; Central Nervous System, Gastroenterology/Urology and Anti-infectives. However, future research efforts will focus on fixed combinations in the treatment of hypertension and the development of therapies for micturition
1. See urination.
2. The desire to urinate.
3. The frequency of urination.
Current Growth Drivers
Zanidip (lercanidipine), an in-house developed calcium channel blocker, is Recordati's top selling product by a considerable margin, accounting for around 15 per cent of the company's total revenue. The product continues to sell well, and Recordati is investing in new combinations and formulations which should ensure future success and growth.
Peptazol (pantoprazole">pantoprazole pantoprazole /pan·to·pra·zole/ (pan-to´prah-zol) a gastric acid pump inhibitor similar to omeprazole, used as the sodium salt in the treatment of erosive esophagitis associated with gastroesophageal reflux disease and of pathological hypersecretion associated with Zollinger-Ellison syndrome or other neoplastic cindition..), a proton pump inhibitor for the treatment of ulcers and gastro-oesophageal reflux disease, has demonstrated good year-on-year growth since its 2002 launch in the Italian market.
Key Late-Phase Products Reaching the Market Place
Zanipress (lercanidipine+enalapril enalapril /enal·a·pril/ (e-nal´ah-pril) an angiotensin-converting enzyme inhibitor used as the maleate salt in the treatment of hypertension, congestive heart failure, and asymptomatic left ventricular dysfunction.) is a new fixed combination treatment for hypertension developed by Recordati. It is currently awaiting approval in Germany, which will act as the reference member state for approval in the rest of Europe. Its launch will support the sales of Zanidip and aid Recordati in making further gains in the European hypertension market.
Fentanyl fentanyl /fen·ta·nyl/ (fen´tah-nil) an opioid analgesic; the citrate salt is used as an adjunct to anesthesia, in the induction and maintenance of anesthesia, in combination with droperidol (or similar agent) as a neuroleptanalgesic, and in the management of chronic severe pain. is a centrally acting, potent analgesic which is being developed as a transdermal patch for the treatment of moderate to severe pin. Recordati has acquired rights to market this product in all the major European markets and the company hopes its launch will expand its analgesic product portfolio.
For more information visit http://www.researchandmarkets.com/reports/c48652